Reinforcing its executive team, Dxcover attracts elite scientific advisors and board members of global caliber
In a significant move to support its US expansion and revenue-stage growth, biotech company Dxcover has appointed two new Non-Executive Directors with significant industry experience.
New Members of the Scientific Advisory Board (SAB)
The new members of Dxcover's SAB are:
- Professor Katy Peters, MD PhD, Professor of Neurology and Neurosurgery at Duke University Medical Center. Her expertise in neuro-oncology and clinical trial design will provide deep knowledge of brain cancer care and translational research for diagnostic innovations.
- Professor Emma Crosbie, MBChB(Hons) PhD MRCOG, Professor of Gynaecological Oncology at the University of Manchester and NIHR Research Professor. She specializes in early detection and prevention of endometrial and ovarian cancers, supporting Dxcover's early detection strategies through her clinical trial and biomarker research expertise.
Professor Matthew J. Baker, CEO and inventor of Dxcover, stated that the new appointees' deep clinical insight and strategic expertise will be instrumental in expanding access to Dxcover's platform, broadening its diagnostic menu into additional cancer types, pursuing regulatory milestones, and delivering their technology into the hands of physicians and their patients globally.
New Members of the Board of Directors
Dxcover has also expanded its Board of Directors with the following appointments:
- Professor David Onions, Investor Director representing Norcliffe Capital Limited, with extensive experience in growing and commercializing life sciences and biotech businesses.
- Dr Stephen Little, Non-Executive Diagnostics Director, former Founder & CEO of DxS (sold to Qiagen), and experience in R&D at AstraZeneca Diagnostics and Yourgene Health.
- Dr Holly Butler, Chief Technical Officer and Head of Development at Dxcover.
- Dr Paul Brennan, Reader and Honorary Consultant Neurosurgeon at the University of Edinburgh, with expertise in brain tumors and clinical trials, and founder of a surgical simulation spin-out.
These individuals bring expertise across neurology, oncology (gynaecological, pancreatic, brain cancers), clinical statistics, artificial intelligence, and diagnostics commercialization. Their contributions strengthen Dxcover's mission of developing and commercializing its Multiomic Spectral Analysis platform for improved cancer diagnostics.
Existing SAB Members
The existing SAB members include:
- Dr. Luke Pike MD DPhil, a Radiation Oncologist at Memorial Sloan Kettering Cancer Center (MSKCC), specializing in CNS malignancies.
- Professor William E. Fisher MD FACS, a leading authority in pancreatic surgery and oncology.
- Professor Paul Brennan MB BChir FRCS(Ed) PhD, a globally recognised expert in brain cancer diagnostics.
The appointments of these industry veterans will undoubtedly bolster Dxcover's efforts in advancing early cancer detection and diagnostic innovation, while the commercial and technical leadership of the board supports the company's clinical translation and growth phase.
[1] Source: Dxcover Press Release [3] Source: University of Edinburgh News
- The newly appointed Professor Katy Peters, with her expertise in neuro-oncology and clinical trial design, will bring deep knowledge of brain cancer care and translational research for diagnostic innovations to Dxcover.
- Professor Emma Crosbie, with her focus on early detection and prevention of endometrial and ovarian cancers, will support Dxcover's early detection strategies through her clinical trial and biomarker research expertise.
- Dxcover's new Non-Executive Directors, Professor David Onions, Dr Stephen Little, Dr Holly Butler, and Dr Paul Brennan, bring expertise across neurology, oncology, clinical statistics, artificial intelligence, and diagnostics commercialization to the company.
- The strategic contributions of these board members will be instrumental in expanding access to Dxcover's platform, broadening its diagnostic menu into additional cancer types, pursuing regulatory milestones, and delivering their technology into the hands of physicians and their patients globally.
- The investments made by Norcliffe Capital Limited, represented by Professor David Onions, will aid in the growing and commercializing life sciences and biotech businesses, supporting Dxcover's mission of developing and commercializing its Multiomic Spectral Analysis platform for improved cancer diagnostics.
- The appointments also include Dr Stephen Little, who has experience in R&D at AstraZeneca Diagnostics and Yourgene Health, and Dr Paul Brennan, a globally recognized expert in brain cancer diagnostics, further enhancing Dxcover's strength in the health tech, digital health, and medical-conditions sector.
